After-Hours Movers

SLM (NASDAQ: SLM) 19.8% HIGHER; reported Q4 EPS of $0.32, $0.02 better than the analyst estimate of $0.30.

National Vision (NYSE: EYE) 10.9% HIGHER; adds five additional vision centers, will now manage 231 vision centers within Walmart (WMT) stores

PTC (NASDAQ: PTC) 8.2% HIGHER; reported Q1 EPS of $0.57, $0.13 better than the analyst estimate of $0.44. Revenue for the quarter came in at $356.11 million versus the consensus estimate of $342.16 million. PTC sees FY2020 EPS of $2.15-$2.65, versus the consensus of $2.17. PTC sees FY2020 revenue of $1.445-1.525 billion, versus the consensus of $1.46 billion.

Paycom Software Inc. (NYSE: PAYC) 5.5% HIGHER; will replace WellCare Health Plans Inc. (NYSE: WCG) in the S&P 500

Citrix Systems (NASDAQ: CTXS) 4.8% HIGHER; reported Q4 EPS of $1.71, $0.03 better than the analyst estimate of $1.68. Revenue for the quarter came in at $810 million versus the consensus estimate of $802.03 million. Citrix Systems sees Q1 2020 EPS of $1.15-$1.20, versus the consensus of $1.23. Citrix Systems sees Q1 2020 revenue of $730-740 million, versus the consensus of $740.5 million. Citrix Systems sees FY2020 EPS of $5.35-$5.55, versus the consensus of $5.43. Citrix Systems sees FY2020 revenue of $3.1-3.13 billion, versus the consensus of $3.11 billion.

ProAssurance Corporation (NYSE: PRA) 4.2% LOWER; reported a preliminary estimate of $37 million of adverse development in our prior accident year loss reserves in the fourth quarter of 2019 in our Specialty Property & Casualty segment. This adverse development is in response to deteriorating loss experience, driven by a large national healthcare account written since 2016.

ImmunoGen, Inc., (NASDAQ: IMGN) 3.4% LOWER; announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.

Aviat Networks, Inc. (NASDAQ: AVNW) 3.2% LOWER; Total revenue is expected to be $55.5 to $56.5 million in the fiscal 2020 second quarter and $114.0 to $115.0 million for the fiscal 2020 six-month period. North America revenue is expected to be up $10.5 to $11.5 million and international revenue is expected to be down $21.5 to $22.5 million when comparing the fiscal 2020 and fiscal 2019 six-month periods. (Consensus sees Q2 EPS of $0.51 on revenue of $60.9 million).

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) 2.9% LOWER; announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement.

H.B. Fuller (NYSE: FUL) 2.4% LOWER; reported Q4 EPS of $0.88, $0.04 worse than the analyst estimate of $0.92. Revenue for the quarter came in at $739 million versus the consensus estimate of $744.08 million. H.B. Fuller sees FY2020 EPS of $3.15-$3.35, versus the consensus of $3.50.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) 2.3% HIGHER; announced today that the U.S. Food and Drug Administration (FDA) has notified its collaborators at the Sean M. Healey & AMG Center for Amyotrophic Lateral Sclerosis (ALS) at Massachusetts General Hospital (MGH) that they may proceed with clinical investigation of verdiperstat, Biohaven's novel myeloperoxidase (MPO) inhibitor, in ALS. This will be the second potentially registrational trial of verdiperstat in neurodegenerative disorders. Biohaven has already initiated a separate trial of verdiperstat in multiple system atrophy.